HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

AbstractOBJECTIVE:
To estimate the antitumor efficacy of dolastatin-10 in patients with measurable recurrences of platinum-sensitive ovarian carcinoma and to determine the nature and degree of toxicity of dolastatin-10 in these patients.
METHODS:
Patients received dolastatin-10 400 microg/m(2) intravenously every 3 weeks and tumor measurements were performed every one to two cycles.
RESULTS:
Of 28 patients evaluable for response, there were no complete or partial responses. Seven patients had stable disease and 21 patients had increasing disease.
CONCLUSION:
Dolastatin-10 has minimal activity in recurrent platinum-sensitive ovarian carcinoma at the dose and schedule tested.
AuthorsMark A Hoffman, John A Blessing, Samuel S Lentz, Gynecologic Oncology Group Study
JournalGynecologic oncology (Gynecol Oncol) Vol. 89 Issue 1 Pg. 95-8 (Apr 2003) ISSN: 0090-8258 [Print] United States
PMID12694660 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antineoplastic Agents
  • Depsipeptides
  • Oligopeptides
  • Organoplatinum Compounds
  • dolastatin 10
Topics
  • Adult
  • Aged
  • Antineoplastic Agents (therapeutic use)
  • Depsipeptides
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local (drug therapy)
  • Oligopeptides (adverse effects, therapeutic use)
  • Organoplatinum Compounds (pharmacology)
  • Ovarian Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: